UnitedHealth Group, medicare advantage
CMS withdraws notice of appeal over UnitedHealthcare's MA star ratings lawsuit
· 2d
US drops appeal in case over UnitedHealth Medicare plans' rating
CMS drops appeal in UnitedHealth Medicare Advantage ratings case
CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most dramatic drops in scores. In its lawsuit, the UnitedHealth Group subsidiary alleged the decline improperly cost the company “tens of millions” in federal payments.
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.
Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in the first days of the Trump administration.
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of
The Centers for Medicare & Medicaid Services Jan. 10 proposed a 4.3% payment increase to Medicare Advantage plans for calendar year 2026, amounting to approximately $21 billion. CMS also proposed to complete its implementation of a three-year phase-in of ...
UnitedHealth (UNH) stock in focus as Medicare withdraws appeal over an unfavorable ruling related to the company's 2025-Star Ratings. Read more here.
The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.
The Centers for Medicare and Medicaid Services will issue corrected data on Medicare Advantage enrollment the week of Jan. 20.
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.
The CMS said 24.2 million people signed up during the enrollment window, including 3.9 million new enrollees. That's more than double the number of people who enrolled during the 2021 sign-up period, according to the announcement.
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback